Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Phase 2

Completed

Conditions: Multiple Indications Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2014-11-21

Last Posted Date: 2023-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 17

Registration Number: NCT02297139

Locations: 🇵🇱
Local Institution, Lodz, Poland
🇵🇱
Local Institution - 0006, Kraków, Małopolskie, Poland
🇵🇱
Local Institution - 0002, Wroclaw, Poland

and more 1 locations

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Phase 2

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2014-10-20

Last Posted Date: 2019-11-29

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 131

Registration Number: NCT02268370

Locations: 🇨🇦
McGill University Health Centre, Montreal, Quebec, Canada
🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 9 locations

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Phase 2

Conditions: Diffuse Intrinsic Pontine Glioma

Interventions: Drug: Erlotinib
Drug: Everolimus
Drug: Dasatinib

First Posted Date: 2014-09-08

Last Posted Date: 2018-07-23

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 250

Registration Number: NCT02233049

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

First Posted Date: 2014-05-21

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT02143414

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States

and more 194 locations

Explore the Synergy of Combination TKI Therapy

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: Dasatinib+Imatinib
Drug: Dasatinib

First Posted Date: 2014-05-02

Last Posted Date: 2014-10-06

Lead Sponsor: University of Florida

Registration Number: NCT02129166

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: dasatinib

First Posted Date: 2014-04-14

Last Posted Date: 2014-04-14

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 27

Registration Number: NCT02113319

Locations: 🇫🇷
University Hospital, Angers, France

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Interventions: Drug: Asciminib (ABL001)
Drug: Nilotinib
Drug: Imatinib
Drug: Dasatinib

First Posted Date: 2014-03-07

Last Posted Date: 2024-03-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 326

Registration Number: NCT02081378

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering, New York, New York, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸
Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States

and more 4 locations

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Phase 2

Terminated

Conditions: Endometrial Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Uterine Corpus Cancer
Ovarian Clear Cell Cystadenocarcinoma

Interventions: Drug: Dasatinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-02-11

Last Posted Date: 2023-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT02059265

Locations: 🇺🇸
Illinois CancerCare-Princeton, Princeton, Illinois, United States
🇺🇸
Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States
🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States

and more 223 locations

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Phase 2

Terminated

Conditions: Acute Lymphocytic Leukemia
Adult Lymphoblastic Lymphoma

Interventions: Drug: DNR
Drug: VCR
Drug: PEG-asp
Drug: CTX
Drug: Prednisone
Drug: Liposomal AraC
Drug: MTX
Drug: LCV
Drug: AraC
Drug: Etoposide
Drug: Dasatinib
Drug: Rituximab
Drug: Hydrocortisone

First Posted Date: 2014-01-23

Last Posted Date: 2022-05-02

Lead Sponsor: University of California, San Diego

Target Recruit Count: 31

Registration Number: NCT02043587

Locations: 🇺🇸
UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center, La Jolla, California, United States
🇺🇸
Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 1 locations

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Not Applicable

Conditions: Recurrent Childhood Brain Tumor

Interventions: Device: Tumor biology testing
Drug: Temozolomide
Drug: Etoposide
Drug: Everolimus
Drug: Erlotinib
Drug: Dasatinib
Drug: Sorafenib

First Posted Date: 2013-12-19

Last Posted Date: 2016-12-15

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 20

Registration Number: NCT02015728

Locations: 🇺🇸
Seattle Children's, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy